Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atorvastatin in TNBC Patients With Residual Disease
NCT03872388Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Sep 2019
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of atorvastatin in triple-negative breast cancer (TNBC) (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Proportions of Patients With Undetectable Circulating Tumor Cells at 6 months. Started Sep 2019; status: terminated.
02
Drugs
atorvastatin
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03872388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03872388.